[The carcinogenic activity of spirobromine].
The carcinogenic activity of spyrobromin was studied during the chronic experiment on 1.5-2-month-old rats and mice of both sexes. The drug was administered intragastrically and intraperitoneally once a week in the maximally tolerant dose for 24 months. Under the given experimental conditions spyrobromin can diminish the latent period of the development of tumours in the experimental rats at intraperitoneal administration. At intragastric administration of the drug no decrease was noted in the latent period and no increase of tumours was observed in the experimental groups of the animals as compared with control. Spyrobromin is considered to be a weak carcinogen. The oral route of administration is the most safe with respect to the oncogenic risk.
O I
OI
Lavrik
V M
VM
Ivanova
L F
LF
Shashkina
L V
LV
Nechushkina
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005260:Female; D015994:Incidence; D008297:Male; D051379:Mice; D009374:Neoplasms, Experimental / Q000139:chemically induced* / Q000453:epidemiology; D051381:Rats; D013045:Species Specificity; D013141:Spiro Compounds / Q000008:administration & dosage / Q000633:toxicity*; D013997:Time Factors
D000970:Antineoplastic Agents; D013141:Spiro Compounds; C054863:spirobromin
Kantserogennaia aktivnost' spirobromina.